Skip to main content
OpenTrials
Completed

NCT Number: NCT03418363

How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills

A randomized study is to learn more about how a supplement called DHEA (dehydroepiandrosterone) affects clotting factors in women taking combined oral contraceptive pills. Current research suggests that the progestin hormone in a specific type of birth control pill may increase a woman's blood clot risk. However, it is unknown exactly how the progestin causes the increased risk. This study aims to learn if taking a daily dose of supplemental androgen (dehydroepiandrosterone, or DHEA) in addition to birth control pills containing DRSP affects proteins related to coagulation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraceptive Usage Behavior Cardiovascular Diseases Coagulation Contraception Behavior Embolism and Thrombosis Reproductive Behavior Thromboembolism Thrombosis Vascular Diseases Venous Thromboembolism

Age range

18 year–44 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Oregon Health & Science University

Portland, Oregon, 97239, United States

About this study

While the pro-thrombotic effects of estrogens are well established in women using combined oral contraception (COC), controversy exists over whether the various synthetic progestogens (progestins) used in combination with ethinyl estradiol in COC formulations may modify the risk of venous thromboembolism (VTE). Several studies have demonstrated that different types of progestins used in COCs influence the magnitude of the estrogen-induced changes in coagulation pathway proteins. However, since hepatocytes do not express progesterone receptor, any activity of a progestin must be indirect. While all progestins on the market are strong agonists for the progesterone receptor (PR), most have variable affinity for the androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). Generations of progestins have been developed, each successive generation exhibiting decreasing levels of androgenicity. Recent epidemiologic studies have suggested an increased risk of VTE in women using low-androgen progestins relative to those using levonorgestrel-containing products. Although no pattern of hepatic globulin changes has been validated as a surrogate marker for thrombosis risk, the overall magnitude of change in various hepatic proteins involved in coagulation is greater with the newer low-androgenic progestins compared to levonorgestrel, leading some experts to suggest that a progestin's androgenic profile may influence the risk of thrombosis. However, a series of well-designed large prospective cohort studies have not confirmed the increased risk of VTE with low-androgen progestins.

A major problem with reconciling the conflicting results from epidemiologic and prospective studies has been the lack of a clear mechanism, as no studies have demonstrated whether these observed changes are mediated through androgen receptor activity. We hypothesize that androgen receptor activity opposes the estrogen receptor-mediated increase in hepatic clotting factors in women using combined oral contraceptives. To test this hypothesis, we propose a randomized clinical trial in which we will enroll healthy women using combined oral contraception containing ethinyl estradiol (EE) with an antiandrogenic progestin (drospirenone, DRSP). Participants will be randomized to treatment with oral androgen (dehydroepiandrosterone, DHEA) or placebo, and we will collect whole blood samples to measure coagulation pathway-related hepatic globulins (APC-r, Protein S, SHBG) before and after treatment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women of reproductive age (18-44 years) in generally good health and with body mass index (BMI) between 18 and 35kg/m2
  • Premenopausal, with uterus and at least one ovary intact
  • Current users (at least 3 months) of combined oral contraception consisting of 0.02 mg (milligram) ethinyl estradiol and 3 mg drospirenone
  • Willing to continue use of current combined oral contraception for the next three menstrual cycles
  • Have a prescription for combined oral contraception consisting of ethinyl estradiol and drospirenone for the next four cycles
  • Not currently using androgen supplementation
  • Willing and able to sign the informed consent
  • Willing to comply with the study requirements and visit schedule
  • No desire to conceive during study participation, approximately 3 months

Exclusion criteria

  • Currently enrolled in another clinical trial
  • Contraindications to androgen supplementation; history of polycystic ovarian syndrome (PCOS)
  • Known or suspected pregnancy, pregnancy within 3 months before study enrollment, or desire to conceive during study participation
  • Currently breastfeeding
  • Known or suspected alcoholism or drug abuse

Treatment and study plan

DHEA Oral Capsule

Dietary Supplement

Daily 100mg DHEA supplement

Placebo oral capsule

Other

Daily oral capsule

Primary outcomes

  1. Change in 3-month plasma levels of APC-r

    Time frame: Baseline & Study Completion (month 3)

    Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of APC-r after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months).

  2. Change in 3-month plasma levels of protein S

    Time frame: Baseline & Study Completion (month 3)

    Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of protein S after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months).

  3. Change in 3-month serum levels of SHBG

    Time frame: Baseline & Study Completion (month 3)

    Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of SHBG after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months).

  4. Change in 3-month serum levels of ethinyl estradiol

    Time frame: Baseline & Study Completion (month 3)

    Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of ethinyl estradiol after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months).

  5. Change in 3-month serum levels of DHEA

    Time frame: Baseline & Study Completion (month 3)

    Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of DHEA after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months).

  6. Change in 3-month serum levels of free and total testosterone

    Time frame: Baseline & Study Completion (month 3)

    Access change in blood levels from baseline (Visit 1) to study completion visit (Visit 2). Collection of whole blood samples from participants to assess change in levels of total testosterone and free testosterone (calculated using serum albumin) after randomization to DHEA supplementation or placebo for 3 cycles (approximately 3 months).

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Official study title

Effect of the Addition of an Oral Androgen (Dehydroepiandrosterone) on Hepatic Globulins in Users of an Antiandrogenic Combined Oral Contraceptive (Ethinyl Estradiol/Drospirenone)

Acronym: COC+DHEA

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Feb 1, 2018
Registry last updated
Jan 23, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.